Asset acquisition

Biotime Inc.

Our attorneys are representing BioTime Inc., a developer and marketer of products in the fields of stem cells and regenerative medicine, in its acquisition, through its subsidiary BioTime Acquisition Corporation, of stem cell assets from Geron Corporation, a biotechnology company. This acquisition will enable BioTime to develop cell therapy technologies to realize the potential of regenerative medicine.

Email Disclaimer